A conserved lysine in the thyroid hormone receptor-́1 DNA-binding domain, mutated in hepatocellular carcinoma, serves as a sensor for transcriptional regulation

Molecular Cancer Research

Volumn 8, Issue 1, 2010, Pages 15-23

  Chan, Ivan H ^a,b   Privalsky, Martin L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Discovery Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSINE; MUTANT PROTEIN; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR ALPHA1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA BINDING MOTIF; GENE MUTATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CONSERVED SEQUENCE; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; LYSINE; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; THYROID HORMONE RECEPTORS ALPHA; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 75149157082     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0425     Document Type: Article

References (46)

1. Harvey CB, Williams GR. Mechanism of thyroid hormone action. Thyroid 2002;12:441-6.
2. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001;81:1097-142.
3. Flamant F, Baxter JD, Forrest D, et al, International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol Rev 2006;58:705-11.
4. Privalsky ML. The role of corepressors in transcriptional regulation by nuclear hormone receptors. Annu Rev Physiol 2004;66:315-60.
5. Lee JW, Lee YC, Na SY, Jung DJ, Lee SK. Transcriptional coregulators of the nuclear receptor superfamily: coactivators and corepressors. Cell Mol Life Sci 2001;58:289-97.
6. Gurnell M, Chatterjee VK. Nuclear receptors in disease: thyroid receptor â, peroxisome-proliferator-activated receptor ã and orphan receptors. Essays Biochem 2004;40:169-89.
7. Cheng SY. Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance. Trends EndocrinolMetab 2005;16:176-82.
8. Gonzalez-Sancho JM, Garcia V, Bonilla F, Munoz A. Thyroid hormone receptors/THR genes in human cancer. Cancer Lett 2003;192:121-32.
9. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng SY, Nauman A. Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. Carcinogenesis 2002;23:25-33.
10. Lin KH, Shieh HY, Chen SL, Hsu HC. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 1999;26:53-61.
11. Lin KH, Zhu XG, Hsu HC, et al. Dominant negative activity of mutant thyroid hormone á1 receptors from patients with hepatocellular carcinoma. Endocrinology 1997;138:5308-15.
12. Privalsky ML. Thyroid hormone receptors, coregulators, and disease. In: Kumar R, O'Malley BW, editors. NR coregulators and human diseases. Singapore: World Scientific Publishing, LTD; 2008, p. 243-80.
13. Puzianowska-Kuznicka M, Nauman A, Madej A, Tanski Z, Cheng S, Nauman J. Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma. Cancer Lett 2000;155:145-52.
14. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J. Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 2002;87:1120-8.
15. Rietveld LE, Caldenhoven E, StunnenbergHG. Avian erythroleukemia: a model for corepressor function in cancer. Oncogene 2001;20:3100-9.
16. Yen PM. Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab 2003;14:327-33.
17. Chan IH, Privalsky ML. Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene 2006;25:3576-88.
18. Wong CW, Privalsky ML. Transcriptional repression by the SMRTmSin3 corepressor: multiple interactions, multiple mechanisms, and a potential role for TFIIB. Mol Cell Biol 1998;18:5500-10.
19. Sharif M, Privalsky ML. V-Erba and C-Erba proteins enhance transcriptional activation by c-Jun. Oncogene 1992;7:953-60.
20. Yoh SM, Chatterjee VK, Privalsky ML. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Mol Endocrinol 1997;11:470-80.
21. Moehren U, Eckey M, Baniahmad A. Gene repression by nuclear hormone receptors. Essays Biochem 2004;40:89-104.
22. Desbois C, Aubert D, Legrand C, Pain B, Samarut J. A novel mechanism of action for V-Erba: abrogation of the inactivation of transcription factor Ap-1 by retinoic acid and thyroid hormone receptors. Cell 1991;67:731-40.
23. Liu MM, Albanese C, Anderson CM, et al. Opposing action of estrogen receptors á and â on cyclin D1 gene expression. J Biol Chem 2002;277:24353-60.
24. Rogatsky I, Zarember KA, Yamamoto KR. Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 2001;20:6071-83.
25. Schmidt ED, Cramer SJ, Offringa R. The thyroid hormone receptor interferes with transcriptional activation via the AP-1 complex. Biochem Biophys Res Commun 1993;192:151-60.
26. Uht RM, Webb P, Nguyen P, et al. A conserved lysine in the estrogen receptor DNA binding domain regulates ligand activation profiles at AP-1 sites, possibly by controlling interactions with a modulating repressor. Nucl Recept 2004;2:2.
27. Zhang XK, Wills KN, Husmann M, Hermann T, Pfahl M. Novel pathway for thyroid hormone receptor action through interaction with jun and fos oncogene activities. Mol Cell Biol 1991;11:6016-25.
28. Starr DB, Matsui W, Thomas JR, Yamamoto KR. Intracellular receptors use a common mechanism to interpret signaling information at response elements. Genes Dev 1996;10:1271-83.
29. Adams M,Matthews C,Collingwood TN, Tone Y, Beck-Peccoz P,Chatterjee KK. Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor â gene. J Clin Invest 1994;94:506-15.
30. Chatterjee VK.Resistance to thyroid hormone, and peroxisome-proliferator- activated receptor ã resistance. Biochem Soc Trans 2001;29:227-31.
31. Collingwood TN, Adams M, Tone Y, Chatterjee VK. Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone â-receptors in thyroid hormone resistance syndrome. Mol Endocrinol 1994;8:1262-77.
32. Matsushita A, Misawa H, Andoh S, et al. Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT. J Endocrinol 2000;167:493-503.
33. Rosen MD, Privalsky ML. Thyroid hormone receptor mutations found in renal clear cell carcinomas alter corepressor release and reveal helix 12 as key determinant of corepressor specificity. Mol Endocrinol 2009;23:1183-92.
34. Safer JD, Cohen RN, Hollenberg AN, Wondisford FE. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. J Biol Chem 1998;273:30175-82.
35. Tagami T, Jameson JL. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone. Endocrinology 1998;139:640-50.
36. Rut AR, Hewison M, Kristjansson K, Luisi B, Hughes MR, O'Riordan JL. Two mutations causing vitamin D resistant rickets: modelling on the basis of steroid hormone receptor DNA-binding domain crystal structures. Clin Endocrinol (Oxf) 1994;41:581-90.
37. Claessens F, Gewirth DT. DNA recognition by nuclear receptors. Essays Biochem 2004;40:59-72.
38. Khorasanizadeh S, Rastinejad F. Nuclear-receptor interactions on DNA-response elements. Trends Biochem Sci 2001;26:384-90.
39. Meyer T, Starr DB, Carlstedt-Duke J. The rat glucocorticoid receptor mutant K461A differentiates between two different mechanisms of transrepression. J Biol Chem 1997;272:21090-5.
40. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 2009;324:407-10.
41. Yu RT, McKeown M, Evans RM, Umesono K. Relationship between Drosophila gap gene tailless and a vertebrate nuclear receptor Tlx. Nature 1994;370:375-9.
42. Chan HI, Privalsky ML. Thyroid hormone receptor (TR) mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire. Oncogene 2009;28:4162-74.
43. Chen H, Smit-McBride Z, Lewis S, Sharif M, Privalsky ML. Nuclear hormone receptors involved in neoplasia: erb A exhibits a novel DNA sequence specificity determined by amino acids outside of the zincfinger domain. Mol Cell Biol 1993;13:2366-76.
44. Judelson C, Privalsky ML. DNA recognition by normal and oncogenic thyroid hormone receptors. Unexpected diversity in half-site specificity controlled by non-zinc-finger determinants. J Biol Chem 1996; 271:10800-5.
45. Sharif M, Privalsky ML. v-erbA oncogene function in neoplasia correlates with its ability to repress retinoic acid receptor action. Cell 1991;66:885-93.
46. Rastinejad F, Perlmann T, Evans RM, Sigler PB. Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature 1995;375:203-11.